Table 1.
Background characteristics and proportion of atrial fibrillation detection.
|
Total (N = 84) |
MVO group (N = 29) |
Non-MVO group (N = 55) |
P-value | |
|---|---|---|---|---|
| Age, mean (SD), years | 68 (11) | 67 (9) | 68 (11) | 0.54 |
| Male sex, No. (%) | 64 (76%) | 21 (72%) | 43 (78%) | 0.56 |
| CHADS2 score after stroke, median (IQR) | 3 (3–4) | 3 (3–4) | 3 (3–4) | 0.55 |
| Congestive heart failure, No. (%) | 5 (6%) | 2 (7%) | 3 (5%) | 0.79 |
| Hypertension, No. (%) | 58 (69%) | 19 (66%) | 39 (71%) | 0.61 |
| Diabetes mellitus, No. (%) | 17 (20%) | 6 (21%) | 11 (20%) | 0.94 |
| Large LADa, No. (%) (n = 81) | 12 (15%) | 4 (14%) | 8 (15%) | 0.92 |
| High BNP or NT-proBNPb, No. (%) (n = 82) | 17 (21%) | 7 (24%) | 10 (19%) | 0.57 |
| Frequent PACsc, No. (%) (n = 66) | 16 (24%) | 7 (29%) | 9 (21%) | 0.48 |
| Endovascular thrombectomy, No (%) | 17 (20%) | 17 (60%) | – | – |
| Onset-to-implantation periodd, median (IQR), days | 21 (14–39) | 18 (14–32) | 23 (13-41) | 0.73 |
| Whole follow-up periode, median (IQR), days | 218 (158–345) | 199 (156–353) | 221 (157–332) | 0.77 |
| AF detection through ICM | ||||
| Within 90 days from ICM implantation, No (%) | 19 (23%) | 12 (41%) | 7 (13%) | <0.01 |
| During total follow-up period, No (%) | 23 (27%) | 13 (45%) | 10 (18%) | <0.01 |
AF, atrial fibrillation; BNP, B-type natriuretic peptide; ICM, insertable cardiac monitoring; IQR, interquartile rage; LAD, left atrial diameter; MVO, major vessel occlusion; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and PAC, premature atrial contraction.
Differences between the MVO and non-MVO groups were evaluated using Fisher's exact test for PAF detection and other categorical variables and the Student t-test and Mann-Whitney U test for continuous variables.
Large LAD was defined as 45 mm or more.
High BNP or NT-proBNP was defined as >100 pg/mL or >300 pg/mL, respectively.
Frequent PAC was defined as the highest quartile of the patients enrolled in the current analysis, i.e., more than 222 beats a day.
Onset-to-implantation days were defined as days from index stroke onset to ICM implantation.
Whole follow-up period was defined as days from ICM implantation to the end of follow-up, i.e., until June 30, 2018.